Machine Learning Automatically Detects COVID-19 using Chest CTs in a
  Large Multicenter Cohort by Georgescu, Bogdan et al.
Machine Learning Automatically Detects 
COVID-19 using Chest CTs in a Large 
Multicenter Cohort 
Authors: 
Bogdan Georgescu, PhD (8), Shikha Chaganti, PhD (8), Gorka Bastarrika Aleman, MD (1), Eduardo Jose Mortani 
Barbosa Jr., MD (6), Jordi Broncano Cabrero, MD (2), Guillaume Chabin (9), Thomas Flohr, apl. Prof., PhD (7), 
Philippe Grenier, Prof., MD (3), Sasa Grbic, PhD (8), Nakul Gupta, MD (4), François Mellot, MD (3), Savvas Nicolaou, 
MD (11), Thomas Re, MD (8), Pina Sanelli, MD (5), Alexander W. Sauter, MD (10), Youngjin Yoo, PhD (8), Valentin 
Ziebandt (7), Dorin Comaniciu, PhD (8) 
 
(1) Clínica Universidad de Navarra, Navarra, Spain 
(2) Health Time, Jaén, Spain 
(3) Hôpital Foch, Suresnes, France  
(4) Houston Methodist, Houston, USA 
(5) Donald and Barbara Zucker School of Medicine,  
Feinstein Institutes for Medical Research,  
Northwell Health, Manhasset, NY, USA 
(6) Penn Medicine, Philadelphia, PA, USA 
(7) Siemens Healthineers, Forchheim, Germany 
(8) Siemens Healthineers, Princeton, NJ, USA 
(9) Siemens Healthineers, Paris, France 
(10) University Hospital Basel, Clinic of Radiology & Nuclear medicine, Basel, Switzerland 
(11) Vancouver General Hospital, Vancouver, Canada 
 
Acknowledgements: 
We gratefully acknowledge the contributions of multiple frontline hospitals to this collaboration. The authors also 
thank the COPDGene for providing the data. The COPDGene study (NCT00608764) was funded by NHLBI U01 
HL089897 and U01 HL089856 and also supported by the COPD Foundation through contributions made to an 
Industry Advisory Committee comprised of AstraZeneca, BoehringerIngelheim, GlaxoSmithKline, Novartis, and 
Sunovion.  We thank many colleagues who made this work possible in a short amount of time. Special recognition 
to Brian Teixeira and Sebastien Piat, who were instrumental for implementing and managing the data 
infrastructure.  
Summary 
Automated classification and triaging of chest computed tomography (CT) scans to distinguish COVID-19 
from other lung diseases or normal scans can augment radiologist diagnostic accuracy and efficiency. 
This manuscript evaluates the performance of multiple machine learning methods (metric-based and 
deep learning) to classify chest CTs in suspected COVID-19 patients.  
Key Points 
• Unsupervised clustering reveals the distribution of key tomographic features such as the percent 
of airspace opacity, percent of ground-glass opacities, percent of high opacity or consolidation, 
percent of peripheral and basilar opacities across COVID-19 and control groups. 
• Test data comprises of COVID-19 positive and COVID-19 negative groups, the latter including a 
balanced distribution of non-COVID-19 pneumonia, interstitial lung disease (ILD), and normal 
chest CT scans. Classification accuracies for COVID-19, pneumonia, ILD, and normal CT scans are 
respectively 86%, 67%, 80%, and 100%, reiterating that there can be an overlap of imaging 
patterns associated with COVID-19 and non-COVID-19 pneumonia, as previously reported in the 
clinical literature. 
• The deep learning (DL) -based classification method shows an overall performance of 0.90 AUC 
with a sensitivity of 86% and specificity of 81%. Machine learning methods applied to 
quantitative chest CT metrics can therefore be valuable to improve diagnostic accuracy in 
suspected COVID-19. 
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ABSTRACT  
Purpose 
To investigate if AI-based classifiers can distinguish COVID-19 from other pulmonary diseases and 
normal groups, using chest CT images. To study the interpretability of discriminative features for COVID-
19 detection. 
Materials and Methods 
Our database consists of 2096 CT exams that include CTs from 1150 COVID-19 patients. Training was 
performed on 1000 COVID-19, 131 ILD, 113 other pneumonias, 559 normal CTs, and testing on 100 
COVID-19, 30 ILD, 30 other pneumonias, and 34 normal CTs. A metric-based approach for classification 
of COVID-19 used interpretable features, relying on logistic regression and random forests. A deep 
learning-based classifier differentiated COVID-19 based on 3D features extracted directly from CT 
intensities and from the probability distribution of airspace opacities. 
Results 
Most discriminative features of COVID-19 are percentage of airspace opacity, ground glass opacities, 
consolidations, and peripheral and basal opacities, which coincide with the typical characterization of 
COVID-19 in the literature. Unsupervised hierarchical clustering compares the distribution of these 
features across COVID-19 and control cohorts. The metrics-based classifier achieved AUC, sensitivity, 
and specificity of respectively 0.85, 0.81, and 0.77. The DL-based classifier achieved AUC, sensitivity, and 
specificity of respectively 0.90, 0.86, and 0.81. Most of ambiguity comes from non-COVID-19 pneumonia 
with manifestations that overlap with COVID-19, as well as COVID-19 cases in early stages. 
Conclusion 
A new method discriminates COVID-19 from other types of pneumonia, ILD, and normal, using 
quantitative patterns from chest CT. Our models balance interpretability of results and classification 
performance, and therefore may be useful to expedite and improve diagnosis of COVID-19.  
 
 
 
  
 INTRODUCTION 
Coronavirus disease 2019 or COVID-19 has caused a global pandemic associated with an immense 
human toll and health care burden across the world (1). COVID-19 can manifest as pneumonia, which 
may lead to acute hypoxemic respiratory failure, which is the main reason for hospitalization and 
mortality. A consensus statement provided by the Fleischner Society indicates the use of lung imaging 
for triage of patients with moderate to severe clinical symptoms, especially in resource-constrained 
environments (2).  The most typical pulmonary CT imaging features related to COVID-19 are multi-focal 
(often bilateral and peripheral predominant) airspace opacities, comprised by ground glass opacities 
and/or consolidation, which may be associated with interlobular and intralobular septal thickening 
(“crazy-paving”) (3). A study comparing the differences between COVID-19 and other types of viral 
pneumonia demonstrated that distinguishing features more typical of COVID-19 are predominance of 
ground glass opacities, peripheral distribution, and vascular thickening (4). A consensus statement on 
the reporting of COVID-19 by Radiological Society of North America (RSNA) indicates the typical 
appearance of COVID-19 as peripheral and bilateral distribution of ground glass opacities with or 
without consolidation or a crazy paving pattern, and possibly with the ‘reverse halo’ sign (5). 
Confirmatory diagnosis of COVID-19 requires identification of the virus on nasopharyngeal swabs via RT-
PCR (reverse transcription - polymerase chain reaction), a test that is highly specific (>99%) but with 
sensitivity ranging from 50-80% (6,7). Given the imperfect sensitivity of RT-PCR and potential resource 
constraints, the role of chest CT imaging for diagnosis of COVID-19 is still under investigation. 
Recently, several groups have shown that COVID-19 can be distinguished from other types of lung 
disease on CT with variable accuracy. Mei et al. showed that chest CT scans in patients who were 
positive for COVID-19 by RT-PCR testing could be distinguished from chest CT scans in patients that 
tested negative with an AUC of 0.92 using machine learning and deep learning (8). While this 
classification is potentially valuable, it is limited by lack of details on the types and distribution of 
findings on negative cases. It is important to be able to distinguish COVID-19 related pulmonary disease 
not just from healthy subjects, but also from other types of lung diseases that are not related to COVID-
19, including other infections, malignancy, ILD and COPD. This is especially important as COVID-19 can 
manifest similarly to other respiratory infections such as influenza, which can lead to confusion in triage 
and diagnosis. Bai et al. showed that an artificial intelligence system can assist radiologists to distinguish 
between COVID-19 and other types of pneumonia by improving their diagnostic sensitivity to 88% and 
specificity to 90% (9). The two cohorts compared in this study are from two different countries, 
therefore the generalizability of their model is limited. Similarly, some of the studies that show 
promising results in classification do not provide a detailed description of imaging cohorts in terms of 
acquisition protocols or countries from which the data is acquired (10,11). This information is important 
since different institutions will have varied CT acquisition protocols and different clinical indications for 
CT usage, which can lead to distinct patient populations. 
In this manuscript, we compute CT derived quantitative imaging metrics corresponding to the typical 
clinical presentation of COVID-19 and evaluate the discriminative power of these metrics for the 
diagnosis of COVID-19. We perform unsupervised clustering of interpretable features to visualize how 
COVID-19 patients differ from controls. We compare the performance of metrics-based classifiers to a 
deep learning-based model. Our large training and test datasets are comprised of chest CTs obtained in 
COVID-19 confirmed patients and negative controls from North America and Europe, making this one of 
the first large studies to demonstrate differences in COVID –19 and non-COVID-19 imaging cohorts 
outside of China. 
MATERIALS AND METHODS 
All authors have either been employed or partially supported by BLINDED. 
Patient Selection and Imaging Data 
The data used in this work has been acquired from 16 different centers in North America and Europe 
after anonymization and ethical review at the respective institutions. Our dataset consists of chest CT 
scans of 1150 patients who were positive for COVID-19, and 946 of chest CT scans of patients without 
COVID-19, including patients with pneumonia (n=159), interstitial lung disease (ILD) (n=177), and 
without any pathology on chest CT (n=610). All CT scans in the COVID-19 cohort from North America 
have been confirmed by an RT-PCR test. The COVID-19 cohort from Europe has been either confirmed 
by an RT-PCR test or diagnosed based on clinical symptoms, epidemiological exposure and radiological 
assessment. The pneumonia cohort consists of cases of patients with non-COVID-19 viral pneumonias, 
organizing pneumonia or aspiration pneumonia. The ILD cohort consists of patients with various types of 
ILD exhibiting ground glass opacities, reticulation, honeycombing and consolidation to different degrees. 
The dataset was divided into training, validation and test sets (see Table 1). Model training and selection 
was performed based on training and validation sets. The final performance of selected models is 
reported on the test dataset. Refer to Table S1 in the supplemental material for detailed breakdown of 
demographic and scanning information for each cohort. Note that some of the information is 
unavailable due to anonymization protocols of some centers. 
Metrics of Airspace Disease Severity 
We computed several metrics of severity based on abnormalities known to be associated with COVID-
19, as well as lung and lobar segmentation. We used a previously developed Deep Image-to-Image 
Network that was trained on a large cohort of healthy and abnormal cases for segmentation of lungs 
and lobes (12). Next, we used a DenseUnet to identify the abnormalities related to COVID-19 such as 
GGO and consolidations (12). Based on these segmentations, we computed thirty severity metrics to 
summarize the distribution, location and extent of airspace disease in the two lungs.  The complete list 
of metrics and their detailed description is provided in the supplementary section. 
Metric-based Analysis 
 
Unsupervised Feature Selection and Clustering 
Mutual information was used to select the metrics of severity that are most discriminative between 
COVID-19 and non-COVID-19 abnormalities. The k best features were incrementally selected based on 
an internal validation split. Based on the selected metrics, an unsupervised hierarchical cluster analysis 
was performed to identify clusters of images that have similar features. The pairwise Euclidean distance 
between two metrics was used to compute a distance matrix and the average linkage method is used for 
hierarchical clustering (13). The resulting clustering was visualized as a heatmap. The Python Seaborn 
package was used for this visualization (14). 
Supervised COVID-19 Classification 
Two metrics-based classifiers were trained based on the thirty computed metrics. First, we trained a 
Random Forest classifier, M1, using k selected features based on mutual information. Subsequently, we 
trained a second classifier that uses logistic regression (LR), after a feature transformation based on 
gradient boosted trees (GBT) (15). For training GBT, we used 2000 estimators with max depth 3 and 3 
features for each split. The boosting fraction 0.8 was used for fitting the individual trees. The LR 
classifier, M2, was trained with L2 regularization (C=0.2). The class weights were adjusted to class 
frequencies for the class imbalance between COVID-19 and non-COVID-19 cases. 
Supervised Deep-learning based COVID-19 classification 
A deep-learning-based 3D neural network model, M3, was trained to separate the positive class (COVID-
19) vs negative class (non-COVID-19). As input, we considered a two-channel 3D tensor, with the first 
channel containing directly the CT Hounsfield units masked by the lung region segmentation and the 
second channel containing the probability map of a previously proposed opacity classifier (12). The 3D 
network uses anisotropic 3D kernels to balance resolution and speed and consists of deep dense blocks 
that gradually aggregate features down to a binary output. The network was trained end-to-end as a 
classification system using binary cross entropy and uses probabilistic sampling of the training data to 
adjust for the imbalance in the training dataset labels. A separate validation dataset was used for final 
model selection before the performance was measured on the testing set. The input 3D tensor size is 
fixed (2x128x384x384) corresponding to the lung segmentation from the CT data rescaled to a 3x1x1mm 
resolution. The first two blocks are anisotropic and consist of convolution (kernels 1x3x3) – batch 
normalization – LeakyReLU and Max-pooling (kernels 1x2x2, stride 1x2x2). The subsequent five blocks 
are isotropic with convolution (kernels 3x3x3) – batch normalization – LeakyReLU and Max-pooling 
(kernels 2x2x2, stride 2x2x2) followed by a final linear classifier with the input 144-dimensional. Figure 1 
shows an overview of our 3D DL classifier. 
RESULTS  
Seven features were selected by computing mutual information between the feature and the class in 
the training dataset of 999 COVID-19 cases and 801 controls (pneumonia, ILD and healthy). Note that 
one case of COVID-19 was excluded from training due to field of view issues, one pneumonia control 
was excluded since the z-axis resolution was less than 10 mm and another pneumonia control was 
excluded due to incorrect DICOM parameters and artifact issues. The features are:  
1) Percent of Ground Glass Opacities 
2) Percent of High Opacity (PHO2) (corresponding to consolidation)  
3) Percent of Opacity (PO) (corresponding to consolidation and ground-glass opacities) 
4) Percent of Opacities in the Periphery (see appendix for definition) 
5) Percent of Opacities in the Rind (see appendix for definition) 
6) Percent of Opacities in the Right Lower Lobe 
7) Percent of Opacities in the Left Lower Lobe  
These features correspond to reported typical COVID-19 characteristics in the clinical literature, i.e., 
multifocal ground glass opacities and consolidation with basilar and peripheral distribution of the 
disease (3) according to the RSNA consensus statement (5) and the CO-RADS classification system, which 
has been proposed to classify the likelihood of COVID-19 based on the presence and extent of these 
findings on a scale of 1-6 (16). Figure 2. demonstrates the hierarchical clustering of these metrics, along 
with the ground-truth diagnosis cohort membership (COVID-19, pneumonia, ILD and healthy) shown on 
the band on the left of heat map. The metric values are standardized and rescaled to a value between 0 
and 1. In Figure 2(a), the clustering is performed on the entire training set of 1800 subjects. The 
probability of belonging to the COVID-19 class increases towards the bottom of the heat map, which 
corresponds to higher values of the metrics, i.e., more opacities (both GGO and consolidation), and 
more peripheral and basilar distribution. The middle of the heatmap shows the ambiguous region, 
where there is an overlap of features from different disease cohorts. Figure 2(b) shows the same 
clustering in the test dataset for each of the disease cohorts. While there is a cluster of COVID-19 
subjects that have characteristic features, there are also many which do not show all characteristics. 
Moreover, some cases of pneumonia and ILD overlap with the typical features of COVID-19 
The seven selected features were used to train a random forest classifier (M1). The performance of this 
classifier on a test dataset has an AUC of 0.80 (95% CI: [0.73, 0.86]) as shown in Figure 3. The figure 
shows bootstrapped ROC and AUC values, along with their 95% confidence intervals, which were 
computed on 1000 samples with replacement. The sensitivity and specificity of this model are 0.74 and 
0.73, respectively. The performance is improved by training a second classifier on all thirty metrics using 
a logistic regression model (M2). The metrics are first transformed to a higher-dimensional space using 
feature embedding with gradient boosted trees. This model produces an AUC of 0.85 (95% CI: [0.80, 
0.90])  with a sensitivity of 0.81 and a specificity of 0.77. While the performance improves, some of the 
interpretability is lost since the features are transformed to a higher dimension. 
Finally, our deep learning-based classifier (M3) has the best performance with an AUC of 0.90 (95% CI: 
[0.85, 0.94]), improving the sensitivity and specificity of the system to 0.86 and 0.81 respectively. The 
improvement is mostly due to a reduction of the false positives from the ILD and non-COVID 19 
pneumonia categories. The optimal operating point for all the models was chosen as the point with the 
shortest distance from the top left corner on the ROC computed on the whole test dataset, without 
bootstrapping (17). The corresponding confusion matrices for the three models are shown in Table 2. 
Figure 4 and Figure 5 illustrate examples of correctly labeled samples by the metrics-based classifier and 
the DL-based classifier. Figure 4 shows typical CT images from COVID-19 patients and Figure 5 shows 
negative examples from ILD and non-COVID-19 pneumonia patients. Overlaid in red are the areas 
identified by the opacity classifier. Figure 6 illustrates examples of cases incorrectly labeled by both 
classifiers and Figure 7 shows cases that are incorrectly labeled by the metric-based classifier but 
correctly labeled by the DL classifier that uses additional texture features extracted directly from the 
images. 
DISCUSSION 
In this research, we evaluated the ability of machine learning algorithms to distinguish between chest 
CTs in patients positive for COVID-19 and a control cohort comprising of chest CTs obtained to evaluate 
other pneumonias, ILD and normal cases. We performed an analysis based on clinically interpretable 
severity metrics computed from automated segmentation of abnormal regions in a chest CT scan, as 
well as a black-box approach using a deep learning system. Unsupervised clustering on selected severity 
metrics shows that while there are dominant characteristics that can be observed in COVID-19 such as 
the presence of ground glass opacities as well as peripheral and basal distribution, these characteristics 
are not observed in all cases of COVID-19. On the other hand, some subjects with ILD and pneumonia 
can exhibit similar characteristics. We found that the performance of the system can be improved by 
mapping these metrics into a higher dimensional space prior to training a classifier, as shown by model 
M2 in Figure 2. The best classification accuracy is achieved by the deep learning system, which is 
essentially a high-dimensional, non-linear model.  
The deep learning method achieves a reduced false positive and false negative rate relative to the 
metrics-based classifier suggesting that there might be other latent radiological representations of 
COVID-19 that distinguish it from interstitial lung diseases or other types of pneumonia. It would be 
interesting to investigate how to incorporate the common imaging features into our 3D DL classifier as 
prior information. The proposed AI-based method has been trained and tested on a database of 2096 CT 
datasets with 1150 COVID-19 patients and 946 datasets coming from other categories. We also show 
how our method compares to the one published by Li et al (10) and found that our method achieves a 
higher AUC as well as sensitivity. Further details are provided in the supplementary section. 
One limitation of this study is that our training set is biased toward COVID-19 and healthy controls. This 
bias could have influenced the specificity for discriminating against other types of lung pathology. 
Another limitation is that the validation set size is relatively small, which might not capture the entire 
data distribution of clinical use cases for proper model selection. Among the strengths of this study are 
the diversity of training and testing CT scans used, which were acquired from a variety of manufacturers, 
institutions, and regions as shown in Table S1, ensuring that our results are robust and likely 
generalizable to different environments. We included not only healthy subjects but also various types of 
lung pathology from ILD and pneumonia to the COVID-19 negative control group.  
The system described in this paper provides clinical value in several aspects. It can be used for rapid 
triage of positive cases, particularly in resource constrained environments where radiologic expertise 
may not be immediately available, whereas RT-PCR results may take up to several hours. This system 
could help radiologist to prioritize interpreting CTs in patients with COVID-19 by screening out lower 
probability cases. In addition to rapidity and efficiency concerns, the output of our deep learning 
classifier is easily reproducible and replicable, mitigating inter-reader variability in manually read 
radiology studies. While RT-PCR will remain the reference standard for confirmatory diagnosis of COVID-
19, machine learning methods applied to quantitative CT can perform with high diagnostic accuracy, 
increasing the value of imaging in diagnosis and management of this disease. 
Furthermore, the algorithms described in this paper could potentially be integrated in a surveillance 
effort for COVID-19, even in unsuspected patients. All chest CT scans for pulmonary and non-pulmonary 
pathology (i.e. coronary artery exams, chest trauma evaluation) would be automatically assessed for 
evidence of COVID-19 lung disease as well as for non-COVID-19 pneumonia and referring clinicians could 
be alerted, allowing more rapid institution of isolation protocols. Finally, it could potentially be applied 
retrospectively to large numbers of chest CT exams from institutional PACS systems worldwide to 
uncover the origin and trace the diffuse of SARS-CoV-2 in communities prior to the implementation of 
widespread testing efforts. 
In the future, we plan to deploy and validate the algorithm in a clinical setting and evaluate the clinical 
utility and diagnostic accuracy on prospective data, as well as to investigate the correlation of the 
proposed metrics with the clinical severity of COVID-19 and disease progression over time. COVID-19 
severity can be further quantified by using features from contrast CT angiography such as detection and 
measurement of acute pulmonary embolism which was reported to be associated with severe COVID-19 
infections (18,19). In addition, a clinical decision models could be improved by training a classifier that 
incorporates other clinical data such as pulse oximetry, cell counts, liver enzymes, etc. in addition to 
imaging features. 
 
SUPPLEMENTAL INFORMATION 
Airspace Disease Severity Metrics 
Metric #1-6: Percentage of Opacity (%) or PO 
The total percent volume of the lung parenchyma that is affected by the airspace disease. Computed for 
both lungs and for each lobe. 
Metric #7-12: Percentage of High Opacity (%) or PHO 
The total percent volume of the lung parenchyma that is affected by severe disease i.e., high opacity 
regions including consolidation and vascular thickening. High opacity is defined as the airspace disease 
region with mean H.U. greater than -200. Computed for both lungs and for each lobe. 
Metric #13-18: Percentage of High Opacity (%) 2  
The total percent volume of the lung parenchyma that is affected by denser airspace disease i.e., high 
opacity regions including consolidation. High opacity is defined as the airspace disease region with mean 
H.U. between -200 and 50. Computed for both lungs and for each lobe. 
Metric #19: Lung severity Score (LSS) 
Sum of severity score for each of the five lobes. Based on PO for each lobe, severity score of a lobe is: 0 
if lobe not affected, 1 if 1-25% is affected, 2 is 25-50% is affected, 3 is 50-75% is affected, 4 is 75-100% 
affected. (20) 
Metric #20: Lung High Opacity Score (LHOS) 
Sum of severity score for each of the five lobes, for high opacity regions only. Based on PHO for each 
lobe, severity score of a lobe is: 0 if lobe not affected, 1 if 1-25% is affected, 2 is 25-50% is affected, 3 is 
50-75% is affected, 4 is 75-100% affected. 
Metric #21: Lung High Opacity Score (LHOS) 
Sum of severity score for each of the five lobes, for high opacity regions excluding vasculature (threshold 
50 HU). Based on PHO for each lobe, severity score of a lobe is: 0 if lobe not affected, 1 if 1-25% is 
affected, 2 is 25-50% is affected, 3 is 50-75% is affected, 4 is 75-100% affected. 
Metric #22: Bilaterality  
True if both right and left lungs are involved, false if only one of the two or none is involved. 
Metric #23: Number of Affected Lobes  
Number of lobes affected by the disease. 
Metric #24: Number of Total Lesions  
Number of affected regions in the lung. 
Metric #25: Number of Peripheral Lesions  
Number of lesions that are in the periphery of the lung. Not including apex and mediastinal regions. See 
Fig S1(a). Any abnormality that intersects with the peripheral border is considered a peripheral lesion. 
(16) 
Metric #26: Number of Lesions in the Rind  
Number of regions that are in the rind of the lung as defined in (17) (See Fig S1(b)). Any abnormality that 
intersects with the “rind” is considered a lesion in the rind. 
Metric #27: Number of Lesions in the Core  
Number of regions that are in the core of the lung as defined in (17) (See Fig S1(b)). Any abnormality 
that does not intersect with the rind, is considered a core lesion. 
Metric #28: Percent of Peripheral Distribution  
Given by the number of peripheral lesions divided by the number of total lesions. 
Metric #29: Percent of Peripheral Lesions 
The total percent volume of the lung parenchyma that is affected by disease for peripheral lesions only. 
Metric #30: Percentage of Ground Glass Opacity 
The total percent volume of the lung parenchyma that is affected by less dense airspace disease i.e., 
lesions which are characterized as GGO only. GGO is defined as the airspace disease region with mean 
H.U. less than -200. 
Comparison with literature 
We compared the models in this work to those published by Li et al(10). They investigated a deep 
learning method to distinguish COVID-19 from community-acquired pneumonia and healthy subjects 
using chest CT. Their proposed DL method is based on extracting 2D features on each CT slice followed 
by feature pooling across slices and a final linear classifier. While the results were promising, the 
distribution of data for train and test was not specified in detail in terms of scanning protocols and 
geography.  
There are two main differences between the DL method proposed in this article and the one proposed 
by Li et al (10). First, our method is fundamentally based on 3D deep learning, which exploits better the 
3D image context, and second, our method is using as input the location of lung regions affected by 
opacities, which focuses the classifier on the regions of interest. 
We trained and tested on our dataset using the published code by Li et al (10) and achieved an AUC of 
0.86 (95% CI: [0.81, 0.91]) as shown in Figure S2. The optimal operating point, which was selected as the 
point closest to the top left corner of the ROC computed on the whole test dataset, without 
bootstrapping, produced a sensitivity of 0.72 and specificity of 0.82. Our best model, M3, on the other 
hand achieved an AUC of 0.9 with a sensitivity of 0.86 and specificity of 0.81.  The confusion matrix is 
shown in Table S2. 
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TABLES 
Table 1. Data-split table. 
Table 2. Metrics based classifier confusion matrices. The models were evaluated with 100 COVID-19 
positive, 30 ILD, 30 pneumonia and 34 healthy scans. The operating point was chosen as the closest 
point to the top left corner on the ROC computed over the test dataset (without bootstrapping).  
 
Ground Truth 
Positive Negative 
COVID-
19 
ILD Pneumonia Healthy 
Positive  74 13 12 0 
2 classes 4 categories Train Validation Test 
Positive COVID-19 1000 50 100 
Negative Pneumonia 113 16 30 
ILD 131 16 30 
Without pathology 559 17 34 
Predicted 
(M1) 
Negative 26 17 18 34 
Predicted 
(M2) 
Positive  81 12 10 0 
Negative 19 18 20 34 
Predicted  
(M3) 
Positive  86 6 12 0 
Negative 14 24 18 34 
 
FIGURES 
Figure 1. Overview of the deep learning based COVID-19 classifier. Preprocessing consists of lung 
segmentation and opacities probability distribution computation (12) followed by a 3D deep neural 
network trained to distinguish between the COVID-19 class and nonCOVID-19 class. 
 
 
 
 
Figure 2. Heat Map of Hierarchical Clustering. This illustrates the unsupervised hierarchical clustering of 
the seven metrics along with cohort membership (COVID-19, pneumonia, ILD and healthy) from the 
entire training set of 1800 cases. The metric values are standardized and rescaled to a value between 0 
and 1. 
  
 
 
Figure 3. Bootstrapped ROCs for discriminating COVID-19 from ILD, pneumonia and healthy control by 
the models proposed in this study. The models were evaluated with 100 COVID-19 positive, 30 ILD, 30 
pneumonia and 34 healthy scans. The 95% confidence intervals (shown as a band) are computed by 
bootstrapping over 1000 samples with replacement from the predicted scores. 
 
Figure 4. Examples of correctly classified COVID-19 positive samples from both methods. Red marks 
abnormalities associated with COVID-19.
 
 
Figure 5. Examples of correctly classified negative samples from both methods – top row ILD, bottom 
row Pneumonia. Red marks abnormalities. 
 Figure 6. Examples of incorrectly classified samples by both methods: top-row COVID-19 (FN), middle-
row ILD (FP), bottom-row Pneumonia (FP). Red marks abnormalities. 
 
Figure 7. Examples of samples correctly classified by the DL classifier but incorrectly classified by the 
metric-based classifier. Red marks abnormalities. 
 
 
SUPPLEMENTARY TABLES 
Table S1 
 
COVID-19 
# Data Sets Train: 1000 Validation: 50 Test: 100 
Data Origin EU: 810; North America: 
190 
EU:40; North America: 10 EU:46; North America: 54 
Sex F:232, M:345, 
Unknown:423 
F:15, M:18, Unknown:17 F:27, M:57, Unknown:16 
Age Median:61 yrs, IQR: 49-73 Median:61 yrs, IQR: 50-74.5 Median:49 yrs, IQR:39-66 
Manufacturer Siemens: 777; GE: 135; 
NMD: 22; Philips: 10; 
Toshiba: 20; Unknown: 36 
Siemens: 33; GE: 9; NMD: 2; 
Philips: 3; Toshiba: None; 
Unknown: 3 
Siemens: 21; GE: 35; NMD: 
11; Philips: 11; Toshiba: 16; 
Unknown: 17 
Slice Thickness 
[mm] 
<1.5: 831; [1.5,3]: 124; >3: 
6; unknown:39 
<1.5: 39; [1.5,3]: 11; >3: None <1.5: 41; [1.5, 3]: 48; >3: 11 
Reconstruction 
kernel 
Hard: 842 Soft: 97; 
Unknown: 61 
Hard: 39; Soft:8; Unknown: 3 Hard:25; Soft:57; 
Unknown: 18  
ILD 
# Data Sets Train: 131 Validation: 16 Test: 30 
Data Origin North America: 131 North America: 16 EU:5; North America:25 
Sex F:54, M:54, Unknown:23 F:9, M:4, Unknown:3 F:13, M:14 Unknown:3 
Age Median:59 yrs, IQR: 56.5-
73 
Median:58 yrs, IQR: 50-69.25 Median:66 yrs IQR:53.5-
75.75 
Manufacturer Siemens: 43; GE: 55; 
Philips: 7; Toshiba: 5; 
Unknown: 21 
Siemens: 16;  Siemens: 24; GE: 1;  
Unknown: 5 
Slice Thickness 
[mm] 
<1.5: 16; [1.5,3]: 54; >3: 
13; Unknown: 48 
<1.5: 14; [1.5,3]: 1; >3: 1 <1.5: 28; [1.5, 3]: 1; >3: 1 
Reconstruction 
kernel 
Hard: 15; Soft: 73; 
Unknown: 43 
Hard: 0; Soft:2; Unknown: 14 Hard: 5; Soft:0; Unknown: 
25  
Pneumonia 
# Data Sets Train: 113 Validation: 16 Test: 30 
Data Origin EU:31; North America: 82 North America: 16 North America: 30 
Sex F:53, M:53, unknown:7 F:8, M:5, Unknown:3 F:11, M:14, Unknown:5 
Age Median:70 yrs, IQR: 49-73 Median:60 yrs, IQR: 50-73.75 Median:56 yrs IQR:41.5-66 
Manufacturer Siemens: 70; GE: 7; 
Philips: 1; Toshiba: 2; 
Unknown:33 
Siemens: 14 , GE:1; 
Unknown:1 
Siemens: 25; GE: 5 
Slice Thickness 
[mm] 
<1.5: 58; [1.5,3]: 16; >3: 
39 
<1.5: 13; [1.5,3]: 1; >3: 2 <1.5: 26; [1.5, 3]: 4; >3: 0 
Reconstruction 
kernel 
Hard: 85; Soft: 12; 
Unknown:16 
Soft: 1; Unknown:15  Hard: 1; Soft: 3; 
Unknown:26  
Healthy 
# Data Sets Train: 559 Validation: 17 Test: 34 
Data Origin North America: 559 North America: 17 North America: 34 
Sex F:302, M:209, 
Unknown:48 
F:8, M:8, Unknown:1 F:17, M:17 
Age Median:57 yrs, IQR: 45-66 Median:60 yrs, IQR: 56-64  Median:61 yrs, IQR: 56.25-
65.75 
Manufacturer Siemens: 291; GE: 184; 
Philips: 16; Toshiba: 7; 
Unknown: 61 
Siemens: 7; GE: 6; Philips: 3; 
Toshiba: 1  
Siemens: 11; GE: 10; 
Philips: 9; Toshiba: 4 
Slice Thickness 
[mm] 
<1.5: 515; [1.5, 3]: 43; >3: 
1 
<1.5: 0; [1.5, 3]: 14; >3: 3  <1.5: 6; [1.5, 3]: 23; >3: 5  
  
Table S2. Confusion matrix for the model from Li et al. The operating point was chosen as the closest 
point to the top left corner on the ROC computed over the test dataset (without bootstrapping). 
Li et al 
GT 
Positive Negative 
COVID-
19 
ILD Pneumonia Healthy 
Predicted 
Positive  72 6 10 1 
Negative 28 24 20 33 
 
SUPPLEMENTARY FIGURES 
Figure S1 (a) Shows the periphery region. This definition excludes the apex and mediastinal border. (b) 
Shows the core and rind regions. 
 
 
Reconstruction 
kernel 
Hard: 149; Soft: 19; 
Unknown: 391 
Hard: 4 Soft: 12, Unknown: 1 Hard: 12 Soft: 22 
 Figure S2. Bootstrapped ROCs for our 3D DL classifier and the model proposed by Li et al (10). For the 
model proposed by Li et al, we trained and tested on our dataset using the code provided by the 
authors. The 95% confidence intervals (shown as a band) are computed by bootstrapping over 1000 
samples with replacement from the predicted scores. 
 
 
 
